TY - JOUR

T1 - Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies

AU - Kositsyn, Yuriy M.

AU - De Abreu, Murilo S.

AU - Kolesnikova, Tatiana O.

AU - Lagunin, Alexey A.

AU - Poroikov, Vladimir V.

AU - Harutyunyan , Hasmik S.

AU - Yenkoyan, Konstantin B.

AU - Kalueff, Allan v.

N1 - Текст о финансировании #1 This work was supported by the Republic of Armenia State Committee of Science (N 10-14/23-I/YSMU) and the European Union-funded H2020 COBRAIN project (857600). The funders had no role in the design, analyses and interpretation of the submitted study, or decision to publish. Текст о финансировании #2 Computer-aided prediction of biological activity in this pharmacotherapeutic field (A.A.L. and V.V.P.) was overviewed within the framework of the Program for Basic Research in the Russian Federation for a long-term period (2021–2030) (project 122030100170-5). The research partially used the facilities and equipment of the Resource Fund of Applied Genetics MIPT (support grant 075-15-2021-684). A.V.K. is supported by St. Petersburg State University 2023 budget assignment funds. T.O.K. is supported by Neurobiology program of Sirius University of Science and Technology 2023 research budget funds. The authors thank Hasmik Harutyunyan (COBRAIN Center, Yerevan State Medical University) for help with graphical illustrations.

PY - 2023

Y1 - 2023

N2 - Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development. © 2023 by the authors.

AB - Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development. © 2023 by the authors.

UR - http://www.scopus.com/inward/record.url?partnerID=8YFLogxK&scp=85161707246

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=001006546200001

U2 - 10.3390/ijms24119482

DO - 10.3390/ijms24119482

M3 - Review article

VL - 24

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

M1 - 9482

ER -